PixarBio Corp (PXRB)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:PixarBio Corp (PXRB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013371
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PixarBio Corp (PixarBio), formerly BMP Holdings Inc., is a biotechnology company that develops novel neurological drug delivery systems for postsurgical pain, acute pain and chronic pain. The company focuses on the research and commercial development of targeted drug delivery systems, devices and biologics to treat Parkinson’s disease, epilepsy, pain and spinal cord injury. Its lead product platform, NeuroRelease, facilitated the sustained release of non-addictive and non-opiate drugs in post-operative, acute and chronic pain in pre-clinical models. It helps reduce pain signals without impeding locomotion signals. The company has offices in New Hampshire, New York and New Jersey, the US. PixarBio is headquartered in Medford, Massachusetts, the US.

PixarBio Corp (PXRB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
PixarBio Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PixarBio Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PixarBio Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PixarBio Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
PixarBio Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
PixarBio Corp, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
PixarBio Raises USD7.2 Million in Venture Financing 11
Merger 12
BMP Holdings Merges with PixarBio in Reverse Merger Transaction 12
Equity Offering 13
PixarBio Raises USD0.8 Million in Financing 13
PixarBio Raises USD7.2 Million in Private Placement of Shares and Warrants 14
PixarBio Corp – Key Competitors 15
PixarBio Corp – Key Employees 16
PixarBio Corp – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Strategy And Business Planning 18
Dec 21, 2016: PixarBio Establishes the JP Reynolds Research Center in Woburn, MA to Advance In-house Research Portfolio in Epilepsy, Spinal Cord Injury, and Non-Addictive Pain Platform 18
Corporate Communications 19
Dec 20, 2016: PixarBio appoints new COO 19
Jul 11, 2016: World Renowned Entrepreneur Laura Morse Joins PixarBio’s Board of Directors as PixarBio Prepares for SEC Compliance 20
Feb 22, 2016: PixarBio Turns Focus To Commercialization in 2018 for NeuroRelease a Non Opiate, Non Addictive Pain Treatment, Adding Industry Sales Veteran Taunia Markvicka as Chief Commercial Officer 21
Product News 22
12/20/2016: PixarBio Names Steve Chartier Chief Operating Officer, To Lead Regulatory Affairs, CMC, and Clinical Studies for NeuroRelease a Morphine Replacement, Non Addictive Pain Treatment 22
10/20/2016: PixarBio Expands PPM to $40,000,000, Extends PPM One Week to Close October 28, 2016 and Promotes Ken Stromsland to Vice President, CIO & External Communications 23
10/17/2016: PixarBio Discusses NeuroRelease a Non-Addictive Morphine Replacement at the 2016 SeeThruEquity Conference in New York City on October 17, 2016 24
10/13/2016: PixarBio Co-Founder and MIT Professor Dr. Robert S. Langer to Discuss the Evolution of NeuroRelease, a Non-Opiate and Non-Addictive Morphine Replacement 25
09/15/2016: PixarBio CEO Frank Reynolds to Present NeuroRelease a Non-Addictive Morphine Replacement at the 2016 Aegis Capital Growth Conference in Las Vegas, NV on September 21, 2016 26
06/27/2016: PixarBio Promotes David Kaplan to Chief Commercial Officer, as NeuroRelease a Morphine Strength Non Addictive Pain Treatment Remains on Track for 2018 Launch 27
03/30/2016: PixarBio, the Developers of NeuroRelease A Revolutionary Morphine Strength, Non-Addictive Pain Treatment Appoints Glenn Reiser Vice President of External Affairs 28
03/03/2016: PixarBio’s Dr. Taunia Markvicka and Glenn Reiser to Discuss Breakthrough Data on Morphine Strength Non-Addictive Pain Treatment NeuroRelease at the 2016 Congress of Neurological Surgeons Spine Summit held in Orlando, FL March 17-18, 2016 29
01/27/2017: PixarBio CEO Frank Reynolds to Present NeuroRelease a Morphine Replacement, Non-Opiate, Non Addictive Pain Treatment at the 2017 NobleCon13 Investor Conference in Boca Raton, FL on Monday, January 30, 2017 30
01/09/2017: PixarBio Expands Non-Opiate R&D Portfolio For Pain with Steroid Injections; Collaborates for Clinical cGMP Manufacturing, and Grooms Team For Clinical Studies of NeuroRelease Post-Surgical Pain Treatments 14-Day, 7-Day, and 3-Day 31
01/05/2017: PixarBio CEO Frank Reynolds to Present NeuroRelease a Morphine Replacement, Non-Opiate, Non Addictive Pain Treatment at the 2017 Biotech Showcase in San Francisco 32
Product Approvals 33
Mar 18, 2016: PixarBio Announces USFDA OPD Submission of NeuroRelease SCI for Orphan Drug Designation for Spinal Cord Injury 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
PixarBio Corp, Pharmaceuticals & Healthcare, Key Facts 2
PixarBio Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PixarBio Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PixarBio Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PixarBio Corp, Deals By Therapy Area, 2011 to YTD 2017 9
PixarBio Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
PixarBio Raises USD7.2 Million in Venture Financing 11
BMP Holdings Merges with PixarBio in Reverse Merger Transaction 12
PixarBio Raises USD0.8 Million in Financing 13
PixarBio Raises USD7.2 Million in Private Placement of Shares and Warrants 14
PixarBio Corp, Key Competitors 15
PixarBio Corp, Key Employees 16
PixarBio Corp, Other Locations 17
PixarBio Corp, Subsidiaries 17

★海外企業調査レポート[PixarBio Corp (PXRB)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mainstream Renewable Power Ltd:企業の戦略的SWOT分析
    Mainstream Renewable Power Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Minoan Group Plc:企業の戦略・SWOT・財務情報
    Minoan Group Plc - Strategy, SWOT and Corporate Finance Report Summary Minoan Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Sompo Holdings, Inc. (8630):企業の財務・戦略的SWOT分析
    Sompo Holdings, Inc. (8630) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • BARMER GEK:企業の戦略的SWOT分析
    BARMER GEK - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Shield Therapeutics Plc (STX):製薬・医療:M&Aディール及び事業提携情報
    Summary Shield Therapeutics Plc (Shield Therapeutics) is a specialty pharmaceutical company that focus on the development and commercialization products for the treatment of anaemia associated with renal and gastrointestinal disorders. The company’s product portfolio includes Feraccru, a stable, non …
  • Tanfield Group PLC (TAN):企業の財務・戦略的SWOT分析
    Summary Tanfield Group plc (Tanfield Group) is an investment company that offers electrical investments. The company designs and produces electric commercial vehicles for short haul urban fleets. It also produces zero-emission vehicles that deliver better performance to traditional diesel trucks. Ta …
  • Nutra Pharma Corp (NPHC):医療機器:M&Aディール及び事業提携情報
    Summary Nutra Pharma Corp (Nutra Pharma) acquires, licenses and commercializes pharmaceutical products, technologies, homeopathic drugs and ethical drugs for managing cancer, neurological disorders, autoimmune and infectious diseases, including human Immunodeficiency virus (HIV), multiple sclerosis …
  • Aegean Marine Petroleum Network Inc (ANW):企業の財務・戦略的SWOT分析
    Aegean Marine Petroleum Network Inc (ANW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Edward Don & Company:企業の戦略・SWOT・財務情報
    Edward Don & Company - Strategy, SWOT and Corporate Finance Report Summary Edward Don & Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Karnataka Power Corporation Ltd:企業の戦略的SWOT分析
    Karnataka Power Corporation Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • American Family Insurance Group:企業の戦略・SWOT・財務情報
    American Family Insurance Group - Strategy, SWOT and Corporate Finance Report Summary American Family Insurance Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Genera Biosystems Ltd (GBI):企業の財務・戦略的SWOT分析
    Summary Genera Biosystems Ltd (GBL) is a multiplexed molecular diagnostic testing product developer. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pathogens; and PapType is …
  • Mitsubishi Research Institute Inc (3636):企業の財務・戦略的SWOT分析
    Mitsubishi Research Institute Inc (3636) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • NEC Corp (6701):企業の財務・戦略的SWOT分析
    NEC Corp (6701) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Republic Services Inc (RSG):企業の財務・戦略的SWOT分析
    Republic Services Inc (RSG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Northwest Territories Power Corp:企業の戦略的SWOT分析
    Northwest Territories Power Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Horizon Discovery Group Plc (HZD):医療機器:M&Aディール及び事業提携情報
    Summary Horizon Discovery Group Plc (Horizon Discovery) is a life science company that discovers and develops genetically-modified cell lines using a proprietary translational genomics platform. The company offers products such as cell lines, reference standards and in vivo models. It also offers se …
  • Excelsior Capital Ltd (ECL):企業の財務・戦略的SWOT分析
    Excelsior Capital Ltd (ECL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Deoleo SA:企業の戦略・SWOT・財務分析
    Deoleo SA - Strategy, SWOT and Corporate Finance Report Summary Deoleo SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • PT Jakarta International Hotels & Development Tbk:企業の戦略・SWOT・財務情報
    PT Jakarta International Hotels & Development Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Jakarta International Hotels & Development Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structur …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆